Event in Progress:
View the latest research on other companies in the sector.
Oxford Instruments^ (OXIG, Buy at 2,700p) - Investments underpin growth opportunity
Oxford Instruments plc
Final results and outlook in line with recently upgraded estimates. Order book +19.2% cc at £319.6m (H1 £315.7m; 3yr order CAGR 15%) underpins expectations for further progress in the year ahead, despite the uncertain economic outlook. Today's update is further evidence of Oxford's alignment to a n
This is a strong set of numbers in a year beset by inflationary pressure, supply chain disruption, and export licence refusals to China. The highlights read well, the outlook is positive and we reiterate our Buy recommendation.
Oxford Instruments^ (OXIG, Buy at 2,730p) - Strong FY23A; FY24F unchanged.
Oxford Instruments^ (OXIG) - Buy at 2,675p - Upgrades! Further margin upside?
The year has ended well, and Ian Barkshire can step down on a decent upgrade. The outlook remains robust, supported by structural growth drivers around environmental, health and connectivity, and with only a small question mark around UK export licences to China this year we remain positive on the story. We raise our TP from 2,400p to 2,670p and reiterate our Buy recommendation.
Overall trading in H2 has continued to be very strong and much better than we previously expected, despite continued supply chain challenges (although these began to ease in H2) and stiffening UK Government export licence controls to China. With further strong order growth, including from compound
Initial Equity Trading Comments - 13 April 2023
OXIG SBRY DEST NXR BRK SAVE TSCO NRR
Oxford Instruments^ (OXIG, Buy at 2,445p) - FY23F ahead of expectations.
Upgrade confirmation – following the interims on 8 November we are updating our model and confirming the upgrades flagged on the day. The strategy continues to deliver better quality growth in structural growth end markets, and with scope for further margin progression and the potential for M&A (with net cash of almost £100m), we expect OXIG to be able to outperform the wider industrials peer group over at least the medium term. Buy rating maintained.
The strategy continues to deliver better quality revenue growth, margin progression, and with almost £100m cash the balance sheet we expect to see more acquisitions to come. We reiterate our Buy rating. The shares trade on 22x March 2023E before any upgrades.
Interim results marginally ahead and outlook statement in line. Therefore, we make only minor adjustments to our estimates for FX, interest and tax (net impact -2% full year EBITA, +1% EPS). Although we remain mindful regarding the weakening macroeconomic environment, the near-term outlook is under
Oxford's statement indicates that constant currency expectations for the full year remain unchanged, order intake remains strong and ahead of sales and with a robust pipeline across all its end markets. We expect the H1 order book to be c.10% ahead YoY on an OCC basis. In addition, with the signifi
Oxford Instruments has released an in-line half year update which highlights slightly slower progress than expected, but has all the ingredients for a strong H2 – namely pricing materialisation, order book delivery and FX. FY expectations are unchanged. Current trading Oxford has seen continued strong demand in the first half of its financial year and management expects “strong” revenue and adjusted operating profit growth, with organic growth slowing due to global supply change challenges, price increase timing and order book phasing. However, reported growth is supported by FX tailwinds. The balance sheet remains strong with net cash increasing £8m from the year end to £94m (ex-IFRS 16). Order book and outlook It continues to see good y-o-y order growth, with organic orders running ahead of revenues. Management comments that the pipeline remains robust across its end markets and that it anticipates higher H2 production combined with the positive impact of price increases. This visibility drives an unchanged FY outlook. Investment case We view Oxford Instruments as a pioneering company with scope to improve the structure of the group through portfolio and operational adjustments. Select M&A enhances the ‘tidy up’ strategy of the business model, and it is encouraging to see margin enhancement continuing. Oxford Instruments is an attractive asset – on 25 Feb 2022 a proposal for a possible offer from Spectris was confirmed. The suggested price was £31/share (compared to the closing price then at £20.20) and the Board had indicated that it was minded to recommend. This valued Oxford Instruments at CY23E PE of 34.4x, EV/EBITDA of 20.9x and an EV of c.£1.71bn. The approach was subsequently withdrawn on 7 March following Russia’s invasion of Ukraine.
Oxford's results continued the strong progress management has made in recent years (5yr operating margin +540bps to 18.1%; EPS +14% CAGR, b/s transformed), through refinement of the portfolio, realignment around the end customer and more commercially-focused development. We believe there is further
Solid finals and a decent order book Oxford Instruments’ results came in slightly ahead of expectations and continued to show impressive top-line growth and margin progression. The outlook is confident, supported by high levels of activity in its key end markets and reflected in the order book, which is up 27% at organic constant currency. With £85m of net cash on the balance sheet, there is plenty of scope for the organic growth to be complemented by more M&A, or other earnings-accretive capital allocation. Either way, we see more to come and reiterate our Buy recommendation and 2,650p target price. Henry.Carver@peelhunt.com, Harry.Philips@peelhunt.com
FY22 results summary & highlights Revenues grew by 15.3% (+14.5% at constant currency) to £367.3m aided by strong growth in semiconductor, advanced materials, quantum technology and despite supply chain disruption constraining growth across the Group. The adjusted operating margin expanded 30bps – absorbing cost inflation – to 18.1%, increasing operating profit by 16.9% (+15.2% at constant currency) to £66.3m (INVe £63.2m / consensus £65.5m). EPS increased 20.0% to 94.3p (INVe 83.6p / consensus 85.9p) and the dividend by 6.5% to 18.1p (INVe 18.25p / consensus 18.43p). Cash generation reflected growth and order phasing with 84% conversion and Oxford maintains a strong balance sheet with net cash of £85.9m (INVe £76.3m / consensus £48.3m). Order book and outlook Orders were up 19.6% to £423.1m (+24.0% at constant currency) and the order book stands at a record level of £260.2m (+26.6% at constant currency), driven by strong growth across its end markets. A strengthened order book provides good visibility and, despite management expecting continued economic headwinds and supply chain constraints, the FY23 outlook is in-line with expectations. Investment case & valuation We view Oxford Instruments as a pioneering company with scope to improve the structure of the group through portfolio and operational adjustments. Select M&A enhances the ‘tidy up’ strategy of the business model, and it is encouraging to see margin enhancement continuing. Oxford Instruments is an attractive asset – on 25 Feb 2022 a proposal for a possible offer from Spectris was confirmed. The suggested price was £31/share (compared to the closing price then at £20.20) and the Board indicated it was minded to recommend. This valued Oxford Instruments at CY23E PE of 34.4x, EV/EBITDA of 20.9x and an EV of c.£1.71bn. The approach was subsequently withdrawn on 7 March following Russia’s invasion of Ukraine. The shares are trading on a FY23E PE of 24.8x and EV/EBITDA of 14.7x, falling to 23.2x and 13.8x respectively in FY24E.
Oxford's post-close update is positive, with trading "marginally ahead" of expectations despite acknowledgement of the continuing challenges of supply chain disruption and cost inflation. We interpret this to mean c. £2m (c. 3%) ahead at the EBITA level for FY22E. With expected achievement of our p
Key trading highlights Oxford Instruments has released a brief year-end (March) trading update, highlighting that FY22 revenues and adjusted operating profit are to be marginally ahead of management expectations (revenue, INVe £343m – consensus £350m / adjusted operating profit, INVe £63.2m – consensus £62.1m). This strong performance is despite supply chain disruption and cost inflation, and reflects a strong H2 with continued resilience in its end markets. Positive outlook Strong order growth supports a healthy order book moving into FY23 and management expects further margin improvement underpinned by its Horizon strategy which is driving growth, operational efficiencies and an improved service offering. Investment case & valuation We view Oxford Instruments as a pioneering company with scope to improve the structure of the group through portfolio and operational adjustments. Select M&A enhances the ‘tidy up’ strategy of the business model, and it is encouraging to see margin enhancement continuing. Oxford Instruments is an attractive asset – on 25 Feb 2022 a proposal for a possible offer from Spectris was confirmed. The suggested price was £31/share (compared to the closing price then at £20.20) and the Board indicated it was minded to recommend. This valued Oxford Instruments at CY22E PE 36.3x, CY23E PE 34.4x, CY22E EV/EBITDA 22.0x, CY23E EV/EBITDA 20.9x and an EV of c£1.71bn at the time. The approach was subsequently withdrawn on 7 March following Russia’s invasion of Ukraine. On our forecasts, the shares currently trade on a FY22E PE of 24.8x, FY23E PE of 24.2x, FY22E EV/EBITDA of 15.0x, FY23E EV/EBITDA of 14.3x. Next catalyst: FY22 results due on 14 June 2022
FY22 pre-close update; trading ahead A short pre-close update confirmed trading slightly ahead of expectations and further margin progression in spite of the well flagged headwinds we are seeing across the sector. We are upgrading our FY22E adj PBT by 6%, FY23E by 7% and increasing our target price from 2,500p to 2,650p. The company is continuing to break new ground thanks to its “Horizon” continuous improvement programme and we see more to come. We reiterate our Buy recommendation. Henry.Carver@peelhunt.com, Harry.Philips@peelhunt.com, Afonso.Osorio@peelhunt.com
Oxford announced on Monday, later confirmed by Spectris, that it had received a non-binding indicative cash and share proposal from Spectris regarding a possible offer for the Group at 3,100p per share (1,950p in cash + 1,150p in new Spectris shares), valuing Oxford at an EV of £1.7bn. The share pr
We believe that Oxford's key enabling technologies, combined with further self-help through Project Horizon and a net cash balance sheet that provides options, offer potential for sustained, above sector average earnings growth over the next few years. With the shares trading at a reasonable discou
We expect Oxford to benefit from continued strong momentum through its record order book, favourable long-term end market dynamics and its own self-improvement programme. We are encouraged that management sees further medium-term margin upside from 18.0% achieved in H1 (noting many peers achieve &g
Key result highlights include: a strong financial performance, strong demand in its core markets and geographies, and unchanged expectations despite prolonged order conversion, supply chain and cost headwinds. First half results Revenues grew by 21.2% (+26.8% at constant currency) to £170.1m. The adjusted operating margin expanded 70bps to 18.0%, increasing operating profit by 25.9% (+28.0% at cc) to £30.6m. EPS increased 25.6% to 41.2p. An interim dividend of 4.4p is a 7.3% increase compared to last year. Cash conversion of 48% reflects an increase in inventories to support order intake and mitigate supply chain disruption, timing of shipments and a resumption in capex. The balance sheet remains strong with net cash of £70.1m. Outlook Orders grew 18.3% at cc and the order book was 13.3% higher y-o-y providing good visibility for the year ahead. Management expects supply chain pressures to moderate conversion of orders to revenue and drive cost inflation in the second half, but given the strong opportunity pipeline and order book, their expectations of further progress in the year are unchanged. Management suggests that the consensus FY22E adjusted operating profit is £62.9m (INVe £63.2m). Note: on 21 September the trading update suggested a FY22 outcome ahead of the then top of the range £63.0m. Investment case We view Oxford Instruments as a pioneering company with scope to improve the structure of the group through portfolio and operational adjustments. Select M&A enhances the ‘tidy up’ strategy of the business model and it is encouraging to see margin enhancement continuing. We admire the business model and its prospects, but believe this is reflected within its current valuation multiples. We remain at Hold. The shares trade on a FY22E PE of 28.7x and EV/EBITDA of 17.5x, falling to 28.0x and 16.6x respectively in FY23E.
Oxford’s brief update indicates that trading is slightly ahead of current market expectations (consensus EBITA £61.2m; range £59.7m-63.0m) and therefore we increase our bottom-of the range EBITA of £59.7m by 5% to £62.6m. Strong current trading momentum means we expect good progress in H1 and we es
Oxford Instruments has released a brief but positive trading update ahead of its AGM today, highlighting strong trading with the full year to be slightly ahead of expectations. Current trading – Strong across the Group Order and revenue growth has been strong in the first five months of the year (March year-end), supported by positive underlying demand across its markets, and across both commercial and academic customers. As expected, FX has adversely impacted revenues and operating profit and at current rates provides a FY22 headwind of 4% and 3% respectively (INVe 5% and 4%). Outlook – positive and ahead of expectations A healthy pipeline across its end markets, a strong order book and acquisition contribution give management confidence that the full year will be ‘slightly ahead of expectations’ (company compiled FY22 adjusted operating profit forecast range of £59.7-63.0m – an average of £61.2m – INVe £60.8m), despite ongoing uncertainties including supply chain disruptions. Investment case – expanding margins and strong balance sheet We view Oxford Instruments as a pioneering company with scope to improve the structure of the group through portfolio and operational adjustments. Select M&A enhances the ‘tidy up’ strategy of the business model and it is encouraging to see margin enhancement continuing. We admire the business model and its prospects, but believe this is reflected within its current valuation multiples. We remain at Hold. On our current forecasts, the shares trade on a FY22E PE of 29.2x and EV/EBITDA of 17.4x, falling to 28.5x and 16.6x respectively in FY23E. Upcoming catalyst Management is hosting an analyst day tomorrow, 22 September, to review its quantum technology facilities in Abingdon and its half-year results are due on 9 November.
The scientific instruments specialist announced on 16 June 2021 a modestly sized acquisition. The Group is purchasing WITec GmbH for cash consideration of €42m (c£36m), this includes a €5m performance related element over the 12 months following completion. Based in Ulm, Germany, WITec is a specialist in Raman microscopy imaging solutions. The transaction is subject to regulatory approval from the Federal Ministry for Economic Affairs and Energy, completion is thus expected in the period up to end September this year. Following the acquisition and assuming a lower effective tax charge, we upgrade or FY22F adj. dil EPS by 4.5% from 81.9p to 85.6p. We also note the potential FX headwind particularly in FY23F therefore only expect adj. EBITA to improve marginally year-on-year with growth thereafter (i.e. in FY24F onwards). Oxford currently trades on a FY22F PER multiple of 26.6x, EV/EBITDA ratio of 17.0x and a dividend yield of 0.8%. The valuation continues to be supported by cash flows and the earnings growth potential coming from secular organic growth in instrumentation, through acquisition potential and through further leveraging business performance driving the EBIT margin higher (the Horizon strategy). We retain a BUY stance with a fair value of 2,635p (c16% upside).
A good fit Oxford has announced the acquisition of German-based WITec GmbH, a leading provider of Raman microscopy imaging solutions for €42m. The deal looks a good fit, and is earnings accretive in year 1. We see more to come and reiterate our Buy recommendation and 2,500p target price. Henry.Carver@peelhunt.com, Harry.Philips@peelhunt.com, Jolyon.Wellington@peelhunt.com, Afonso.Osorio@peelhunt.com
New numbers post prelims; another margin beat After the prelims yesterday we are putting through a 4% upgrade to FY22E EPS and introducing FY24 forecasts. The results were positive, with project Horizon still showing that it is delivering improvements in customer intimacy and operational performance that is resulting in better margins. With a favourable backdrop in structural growth markets we see more to come and reiterate our Buy recommendation. Henry.Carver@peelhunt.com, Harry.Philips@peelhunt.com, Jolyon.Wellington@peelhunt.com, Afonso.Osorio@peelhunt.com
Oxford Instruments (‘Oxford’), the scientific instruments and services specialist, servicing academic and industrial laboratories and processes globally, confirmed a strong operating performance for the year to end 31st March 2021 on 8th June 2021 despite the challenging market conditions. The FY results published showed targeting much improved performance metrics, driving sustainable long-term growth and improved margins. Overall revenue, adj. EBITA and adj. PBT were in line with our March 2021 revised expectations with adj dil EPS c3% ahead of our forecast due to a lower effective tax charge. Despite the adverse currency impact going into FY2022F and the ongoing COVID-19 uncertainties with regards to economic recovery, Oxford remains well positioned in our view. Following the challenges with regards to onFY2022F to be realised. As a result, we upgrade our adj. EBITA and adj. PBT by 3.5% to £62.1m and £61.2m respectively and adj. dil EPS (assuming a 22% effective tax rate) by 3.4% to 81.9p. Oxford trades on an FY2022F PER of 25.6x, EV/EBITDA of 15.4x and a dividend yield of 0.8%. As we move forward our valuation model one year ahead, we increase our fair value by c10% from 2,400p to 2,635p which implies an upside of c26%. We retain our Buy recommendation.
Meeting Notes - Apr 01 2021
OXIG MAB1 BAKK QLT HSV
Oxford’s update on Friday reflected the strong recovery many of Oxford’s end markets have enjoyed since the nadir of the COVID-19 pandemic last year as well as further operational benefits from Project Horizon. Unsurprisingly, management highlighted semiconductor applications and China as particula
Oxford Instruments (‘Oxford’), the scientific instrument specialist, has today issued a short but very positive trading update (26 March 2021) in relation to its March year-end. Overall, the Group has made good progress in H2 FY2021 and maintained its good order growth (especially across Asia given performance from China has been strong). Oxford’s end markets have remained resilient with the strongest growth across its semi-conductor applications. As a result, the Board now expect FY2021F revenue to be marginally ahead year-on-year (post a small FX impact) and adj. operating profit to be between £55m to £57m with the latter being supported by realised operating efficiencies (i.e. cost saving measures). Therefore, we upgrade our revenue by 7% from £296.1m to £318m and adj. EBITA by 15% from £49.6m to £57m, which implies an operating margin of 17.9% (compared to our previous expectations of 16.8%). This equates to an adj. dil EPS upgrade of 16% from 65.7p to 76.1p (assuming an effective tax rate of 21%). We would also expect a flow-through into FY2022F (i.e. a c7% adj. EBITA upgrade to £59.7m) given the strong operating performance. We continue to see a positive outlook for further sustained margin improvement, with good forecast upgrade potential given the long-term prospects in instrumentation, with global expertise in critical areas of technology. We retain a BUY stance with a fair value of 2,400p (c34% upside) based on growing FY2020A adj. dil EPS (69.4p) by 10-12% for five years, sustaining a 30x PER and discounting back to present value at 10%.
Positive surprise; TP up to 2,500p Oxford Instruments has issued a short, unscheduled announcement guiding to a FY21 operating profit range some 17% ahead of PHe and even further ahead of consensus. This is thanks to an impressive top line performance but the real beat is at the operating margin, with the implication being that it is running some 150bp ahead of our assumptions. Clear signs of the fundamental improvements coming through from Project Horizon. With a 17% upgrade to PHe FY21 EPS and 18% upgrade to FY22 we increase our TP to 2,500p and reiterate our Buy recommendation. Henry.Carver@peelhunt.com, Harry.Philips@peelhunt.com, Jolyon.Wellington@peelhunt.com, Afonso.Osorio@peelhunt.com
We see further positive momentum in the Oxford story. A combination of significant indicators within the interim results, further self-help through Project Horizon, strong balance sheet to be utilised and attractive market backdrop, keeps us interested. We believe our estimates are conservative, wi
The specialist scientific instruments manufacturer published a robust set of half-year results for the six months to 30 September 2020. Despite the negative impact of COVID19 on its customers, the interims were ahead of market expectations. The results showcased the resilience of the business with the Horizon cost efficiency strategy delivering stable operating margins despite the decline in revenues. The Board expects the FY2021F performance to be “a little behind last year on a constant currency basis” but ahead of current market expectations. We upgrade our FY2021F adj. PBT by c23% to £48.5m and adj. dil EPS by c26% to 66.5p. Based on our upgraded forecasts, Oxford trades on an FY2021F PER of 31.7x (falling to 28.5x in FY2022F), an EV/EBITDA of 18.8x (falling to 16.5x) offering a dividend yield of 0.7%. We continue to see further sustained margin improvement, with solid long-term prospects in instrumentation and global expertise in critical areas of technology, driving forecast upgrade potential. We retain a BUY recommendation with a fair value of 2,400p (c15% upside).
FY20 results highlight progress, profits ahead of expectations Oxford posted strong full-year results highlighting good progress despite the impact of Covid-19 in the latter part of its financial year to March. Revenues grew by 1.1% (-0.7% at constant currency) to £317.4m. The adjusted operating margin expanded 70bps to 15.9% (15.1% at constant currency), increasing operating profit by 5.9% (-1.0% at constant currency) to £50.5m (INVe £47.5m – guided range £47-50m given on 18th March). EPS increased 12.7% to 70.2p. The final dividend is under review, as expected, following the suspended interim dividend. Cash generation was strong and Oxford maintains a strong balance sheet with net cash of £67.5m, driven by cash conversion of 124% and disposal proceeds. Outlook clouded by Covid-19, but many future positives Orders were up 0.3% to £336.0m (-1.3% at constant currency and a book-to-bill of 1.06x) and the order book stands at £175.0m (+12.1% at constant currency), driven by finished goods not shipped or installed by the year-end. Covid-19 related disruptions have impacted the start of its financial year with cumulative orders 3% below a weak comparator period (growth in Asia of 19% offset a reduction in Europe and North America of 23% and 7% respectively). A strong uplift in orders for compound semiconductor process solutions has offset a reduction in orders for higher-margin academic related products. Group revenue is 3% above last year, assisted by delivery of shipments held over from the year-end. We believe Oxford is positioned well with end market resilience and the Group should not be weakened in the long-term by Covid-19 headwinds. Its net cash balance sheet and undrawn facilities give welcome headroom of c£200m. Our view and valuation These were good results with margins, cash and book-to-bill as the highlights; the Group should be will placed for post Covid-19 recovery and there could be scope for some upward consensus revisions. The shares are trading on a FY21E PE of 26.8x and EV/EBITDA of 14.1x. We view Oxford Instruments as a pioneering company with scope to improve the structure of the Group through portfolio and operational adjustments. Recent disposals were welcome ahead of the Covid-19 pandemic and enhance the ‘tidy-up’ strategy of the business model. Given order lumpiness, a lack of visibility in some areas, and full valuation we remain at Hold.
The scientific instruments manufacturer has given helpful guidance on the immediate impact it sees from the Coronavirus on the Group for the current year ending March in its 18th March trading update. We previously had a figure of £54m for EBIT for the year, this is now guided to £47m to £50m due to the impact of the virus in China through the Q4 period to end March and enforced shutdowns at facilities in California. Oxford had substantial known shipments into China in the Q4 period (c22% of full year revenue with much of this in Q4) from its order book, so this was not a surprise to us. We reduce our EBIT expectation for FY2020F to £47m, taking a cautious view, but noting that these delayed order deliveries (we do not expect these to be cancelled) are set to fall into FY2021F. Whilst no guidance is given for FY2021F, we have adjusted our forecasts to account for a material impact on deliveries in the H1 period through to end September in Europe and North America. Recovery will come and for this business we expect secular trends to bounce back robustly – order fulfilment is being delayed, rather than cancelled for this type of equipment. Oxford is well positioned for future success with net cash resources in excess of £50m. We retain a BUY stance given the certainty of recovery.
Oxford Instruments (‘Oxford’), the scientific instrument specialist today announced it has completed the sale of its 47% share in Scienta Omicron, a leading company in Ultra High Vacuum Surface Science to a group of existing shareholders in the JV for a total consideration of £11.7m. In this note, we look to update our forecasts post the sale (albeit just breaking even) and factoring in positive underlying market conditions observed across the sector. Oxford has continued to progress with its Horizon strategy, and we believe management is able to deliver continuous growth and margin development given the breadth of its product portfolio and diverse end markets more than offsetting any political uncertainty. We expect Oxford to continue to benefit operationally from its restructuring programme, increasingly focusing on driving margins to economically sustainable levels, as well as the long-term secular growth trends seen in instrumentation. Oxford trades on an FY2020F PER of 21.4x (EV/EBITDA 13.0x, under IFRS16 leases) falling in FY2021F to a PER of 20.3x (EV/EBITDA 12.3x). We retain our BUY recommendation.
Taiwan exports rise for first time since 2018, IMF cuts global growth forecasts, Boeing in talks to borrow $10bn
OXIG RSW RNO TWD ZTF GHH
US small business sentiment dips in Dec, Japan machine tool orders rise m/m in Dec, Airbus surpasses Boeing in orders
Japanese core machine orders fell in October missing expectations, Construction equipment sales rose in China as Beijing boosts spend
H1’20 results are positive highlighting good growth and margin progress Oxford posted strong half-year results highlighting good growth, margin expansion and robust underlying cash generation. Revenue growth was driven by semiconductors, advanced materials and energy end markets, while the operating margin benefitted from increased revenues and operational improvements. An 8% increase in the interim dividend is encouraging. Revenues grew by 13.1% (9.1% organic) to £166.3m (INVe £160.0m). The operating margin expanded 120bps to 15.5% giving operating profit growth of 22.9% (+12.4% organic growth) to £25.8m (INVe £23.5m). EPS increased by 30.0% to 35.5p while the dividend increased 7.9% to 4.1p. The company remains in a net cash position with £14.2m of net cash at the half-year. Outlook Orders were up 6.4% to £173.3m (+2.8% organic and a book-to-bill of 1.04x) and the order book stands at £186.8m (+6.0% organic). Management expects FY20 to be in-line with expectations with the second half showing a more normal seasonal bias. We believe that consensus has potential to increase by mid-single digit percentage in FY20 when factoring the first half and current FX rates. Our view and valuation We view Oxford Instruments as a work-in-progress, and its recent updates have been reassuring. There has been underlying growth and some currency tailwind, and the full-year expectations were confirmed. Top-line progress has started to drop through to profit, due in part to investment in operational improvement. At this stage – in view of the lumpiness of orders, a lack of visibility in some places, macro constraints and valuation – we remain a Hold. On our current forecasts, the shares are trading on FY20E PE of 20.2x, EV/EBITDA of 11.8x, and dividend yield of 1.1%.
We believe that Oxford’s restructure and recovery programme (project Horizon), continues to progress. Much has been achieved over the past 18 months or so, in our view, revitalising and injecting greater commercial emphasis. This is visible in results, in our view, with more to come over the next two years. Much remains to be achieved in driving out efficiencies and, subject to short term global trade influences, we expect business metrics to continue to improve. Oxford should be well placed to deliver market leading solutions generating sustainable economic returns for shareholders, in our opinion, leveraging secular growth opportunities, in the long-term. Investment in R&D activities, expensed to income, continues at a high level sustaining competitive and technical leadership. In our view, margin potential from greater commercial focus remains, driving upgrade potential with strengthening cash flows and the balance sheet underpinning additional shareholder value creation. We retain a BUY stance.
Renishaw (RSW LN, £2.6bn) Q1 20 (30/09) trading statement – group revenues & metrology revenues both down 19% y/y due to large orders from the APAC region in Q1 19 and “reduced demand for our products as a result of the challenging global macro environment”; adj. PBT down 87% y/y; trading conditions expected to remain challenging through FY20 | Vesuvius (VSVS LN, £1.1bn) Q3 19 (30/09) trading update expects FY19 EBITDA of £180-190m; challenging market environment continued into 2H 19 with further weakening in EMEA | Good Energy (GOOD LN, £24m) awarded Green Economy Classification & Mark by London Stock Exchange
OXIG GHH VSVS GOOD
The heavy Q4 was delivered. The reduction in FY net debt was better than expected despite a short term increase in receivables and represents <0.5x ebitda. The order book grew in H2. FX is now a material headwind and causes us to cut FY19e adj PBT by 7% to £43m. CC growth assumptions are unheroic. Self-help is ongoing with benefits expected from personnel changes and price increases. ROIC is rising and our FY19e net debt improves further as w/c unwinds. A CY18 EV/EBIT of 11x remains attractive, representing a 35% discount to US peers. We note recent director buying of £124k of stock. Our TP is unchanged as this improving business should continue to re-rate.
Oxford Instruments’ AGM update has maintained guidance for the full year, but with a weighting to H2. Revenues and profits for the first five months are down at constant exchange rates, driven by lower sales of optical microscopy products and a change in mix towards magnetic and cryogenic systems which have longer lead times. Revenues for the first five months are flat post FX gains. Management expects a stronger H2 performance due to a combination of normal seasonal bias, plus the impact of new product introductions and FX gains. The shares have been good performers in 2017, reflecting the group’s progress in repositioning the business for growth. However the FY18 profile of a H1 decline and dependence on H2 is unlikely to reassure investors.
Futura Medical (FUM LN) H1 results: Eroxon® trial plan amended; licensing discussions underway | Goals Soccer Centres (GOAL LN) Further downgrades overshadow various strategic positives | Murgitroyd Group (MUR LN) Trading in line after record H2 performance | Oxford Instruments (OXIG LN) FY18 guidance maintained, but dependent on stronger H2 | Summit Therapeutics (SUMM LN) BARDA contract a major boost to ridinilazole | Vernalis (VER LN) Solid FY results driven by NCE collaborations; Tuzistra broadly in line
OXIG GOAL MUR FUM SMMT VER
Clinigen Group (CLIN LN) Recent weakness another opportunity | Oxford Instruments (OXIG LN) FY17 performance in line with previous year | Scapa Group (SCPA LN) Ahead of expectations
OXIG SCPA CLIN
Oxford Instruments has announced the sale of its superconducting wire business to Bruker Corporation for $17.5m in cash. The wire business had seen declining sales and profitability due to competitive pricing pressure in its markets, generating a single digit operating margin in the most recent half year. The disposal will draw a line under these declines and provide a modest but welcome cash inflow to the group’s balance sheet.
Oxford Instruments has been through a very difficult couple of years. End markets have been weak and there have been strong FX headwinds. This has been compounded by the ban on high tech exports to Russia and pricing pressure in MRI superconducting wire. The combination of these events resulted in a series of profit downgrades and a significant de-rating of the shares. However, just as the market got carried away with the attractions of the company in 2012/2013, when the PER rating was well into the twenties, we think that it is now overly negative.
Oxford Instruments has reported FY16 results in line with expectations, with a decline in sales but a 3.6% increase in PBT due to cost saving measures, and a reassuring reduction in net debt/EBITDA. Market conditions remain uncertain, but order intake was almost in line with the previous year, and the first two months of FY17 have seen flat sales and a marginal improvement in profits. We do not anticipate making significant changes to our P&L forecasts, although we expect to reduce our forecast for net debt.
Oxford Instruments has provided a brief year end trading update, confirming trading in line with market expectations after a strong Q4 performance. In a second announcement, CEO, Jonathan Flint, has announced he will step down in May, to be succeeded by COO Ian Barkshire. This completes a clean sweep of management change, with the new FD, Gavin Hill, also starting in May and Chairman, Nigel Keen, due to step down in September. With more solid trading underway and a new management team coming in, we see potential for renewed interest in the group and a positive share price response
Oxford Instruments’ trading update has guided to Q3 performance in line with expectations and confidence in meeting forecasts for the year to March 2016. We read this as a small decline in sales in the period, but an increase in order intake and order book. Meanwhile net debt of £146m has scope to fall below our forecasts by the year end. We do not anticipate making significant changes to our forecasts and would expect a positive share price response.
Oxford instruments has announced the disposal of Austin Scientific, which had already been reported as discontinued in the recent interim results. The small loss-making business has been sold for c.0.25x sales, with proceeds of just $1.3m. We do not anticipate the disposal having a material effect on forecasts.
Oxford Instruments has reported a decline in sales but a 7% increase in PBT for H1 16. Management has reiterated existing guidance, highlighting strong growth in the order book of 15% on an organic basis and 21% in total. Debt covenants have been extended further, giving extra headroom to September 2016. We do not anticipate making significant changes to our forecasts and would expect the share price to reflect investor relief that prospects have not slipped further.
Ahead of the interims, we have reduced our forecasts to reflect the weak AGM update and subdued backdrop, cutting PBT and EPS estimates by 16% for FY16 and 27% for FY17. The shares have been declining as the market has tried to price low confidence in earnings and balance sheet leverage. We see potential for a bounce if the interims are less bad than feared, but also the risk of further downgrades and share price underperformance. We have tried to look through current difficulties and set our 579p target price based on 1.3x EV/sales applied to calendar 2017. Hold.
Oxford Instruments’ AGM update is guiding to reduced expectations for FY16 due to price pressure in superconducting wire and a difficult trading environment for industrial product sales in China. The profit downgrade for the group looks set to be greater than 5% (the negative impact from superconducting wire) but not into double digits (adjusted operating profit is reported to be ahead of the same period last year). We believe that this represents the 11th consecutive quarter of downgrades to consensus forecasts for the group. While the shares are already on a discount to the sector, we would expect further weakness today and would not look to turn more positive until there is evidence of stabilisation in trading.
Oxford Instruments has reported FY2015 results in line with expectations. Management has reiterated expectations for FY16 despite a slow start to the year, due to higher than expected cost savings. However we also note the flat order book and the guidance that £4m of service sales are expected to disappear, which provoke some concerns regarding prospects.
The Q3 trading update issued yesterday reported that whilst H2 revenues are expected to be ahead of H2 last year, they are likely to fall short of expectations, with adjusted PBT anticipated to be about £35m (compared with market forecasts of about £43m to £48m).
Share: